Metastatic cancer is a cagey adversary, a shape- and form-changing disease that can be understood only by following its dynamics at a cellular level. Because most tests are based upon fixed assumptions of what cancer looks like, however, they come up short. For that reason, Epic Sciences chose a research road less traveled, a bias-free approach that looks at all the cells in a non-invasive blood sample, and thus sees those rare cells that others miss.
Every cancer is as unique as the person who carries it. So the tests that diagnose and monitor the illness must be eminently personal, proven and precise.
If you can’t see the problem, you can’t solve it.
Maximizing a revolutionary component: Certainty.
Epic’s new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer. This test requires but a simple blood draw and is unambiguous, giving doctors a clearer picture of a patient's metastatic disease, thus allowing them to proceed with confidence and certainty while sparing patients the anxiety associated with the uncertainty of an uninformed choice.
A bias-free vision of cancer research.
At Epic Sciences, we develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity. Our AR-V7 CTC test, for example, has demonstrated predictive clinical utility for prostate cancer. It’s but one example of our dedication to the development of proven tests to guide therapy selection across the most impactful drug classes in oncology.
New Study Reports Blood Test Can Predict Optimal Treatment for Advanced Prostate Cancer
San Diego, Coherent Chronicle — Researchers from Lawson Health Research Institute suggested that a blood test can help predict efficiency of a treatment in advanced prostate cancer. The Lawson Health Research Institute in collaboration with the Memorial Sloan Kettering Cancer Center and the Royal Marsden and Epic Sciences, demonstrated that a blood test can predict the responses of patients suffering from advanced prostate cancer to specific treatments.
Video - Genomic Sequencing: Precision data to better fight advanced cancer
Portland, KATU2 — Patient Bryce Olson shows the importance of personalized medicine, including the Oncotype DX® AR-V7 Nucleus Detect™ test, in aiding pivotal metastatic castration-resistant prostate cancer treatment decisions. The test, developed by Epic Sciences and commercially available by Genomic Health, is now covered by Medicare.
Video - PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong
San Diego, UroToday — Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progression-free survival and overall survival.
Video - New test extending lives of advanced prostate cancer patients
Bryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.